What is Greenwich Lifesciences Inc's earnings per share (EPS)?

Greenwich Lifesciences Inc (GLSI) reported diluted earnings per share of $-1.21 for fiscal year 2024. This represents a -75.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Greenwich Lifesciences Inc Financials

GLSI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Greenwich Lifesciences Inc (GLSI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Greenwich Lifesciences Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.46x

For every $1 of reported earnings, Greenwich Lifesciences Inc generates $0.46 in operating cash flow (-$7.3M OCF vs -$15.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$15.8M

YoY-77.6%

Greenwich Lifesciences Inc reported -$15.8M in net income in fiscal year 2024. This represents a decrease of 77.6% from the prior year.

EPS (Diluted)

$-1.21

YoY-75.4%

Greenwich Lifesciences Inc earned $-1.21 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 75.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.1M

YoY-41.5%

5Y CAGR+259.3%

Greenwich Lifesciences Inc held $4.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

13M

YoY+2.4%

5Y CAGR+9.2%

Greenwich Lifesciences Inc had 13M shares outstanding in fiscal year 2024. This represents an increase of 2.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-623.1%

YoY-490.4pp

Greenwich Lifesciences Inc's ROE was -623.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 490.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.0M

YoY+68.2%

5Y CAGR+37.8%

Greenwich Lifesciences Inc invested $13.0M in research and development in fiscal year 2024. This represents an increase of 68.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GLSI Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$13.0M+68.2%	$7.7M+18.9%	$6.5M+81.9%	$3.6M+236.6%	$1.1M-59.4%	$2.6M
SG&A Expenses	$3.1M+87.8%	$1.6M+4.1%	$1.6M+50.7%	$1.0M+28.8%	$806K-1.6%	$819K
Operating Income	-$16.0M-71.7%	-$9.3M-16.0%	-$8.0M-74.9%	-$4.6M-146.7%	-$1.9M+45.6%	-$3.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$15.8M-77.6%	-$8.9M-13.6%	-$7.8M-71.2%	-$4.6M-145.3%	-$1.9M+45.6%	-$3.4M
EPS (Diluted)	$-1.21-75.4%	$-0.69-13.1%	$-0.61	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.5M+0.4%	$3.5M+34.9%	$2.6M	N/A	$2.3M-0.7%	$2.3M+5.2%	$2.2M	N/A
SG&A Expenses	$653K+21.4%	$538K-21.0%	$681K	N/A	$437K+23.6%	$354K+3.2%	$343K	N/A
Operating Income	-$4.2M-3.2%	-$4.0M-23.3%	-$3.3M	N/A	-$2.7M-2.5%	-$2.7M-4.9%	-$2.5M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.2M-3.1%	-$4.0M-23.5%	-$3.3M	N/A	-$2.7M-2.4%	-$2.6M-5.4%	-$2.5M	N/A
EPS (Diluted)	$-0.300.0%	$-0.30-20.0%	$-0.25	N/A	$-0.200.0%	$-0.20-5.3%	$-0.19	N/A

GLSI Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$4.1M-41.5%	$7.0M-48.1%	$13.5M-50.5%	$27.2M-5.1%	$28.7M+107419.8%	$27K
Current Assets	N/A	N/A	N/A	N/A	$28.7M+419217.8%	$7K
Cash & Equivalents	$4.1M-41.5%	$7.0M-48.1%	$13.5M-50.5%	$27.2M-5.1%	$28.7M+419217.8%	$7K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M+429.8%	$294K+12.0%	$263K-31.7%	$385K-63.2%	$1.0M-24.1%	$1.4M
Current Liabilities	$1.6M+429.8%	$294K+12.0%	$263K-31.7%	$385K-63.2%	$1.0M-24.1%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.5M-62.2%	$6.7M-49.3%	$13.2M-50.8%	$26.8M-2.9%	$27.6M+2146.1%	-$1.4M
Retained Earnings	-$66.2M-31.3%	-$50.4M-21.4%	-$41.5M-23.3%	-$33.6M-15.7%	-$29.1M-6.8%	-$27.2M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$3.8M+21.8%	$3.1M+13.6%	$2.8M-32.8%	$4.1M-29.7%	$5.8M-19.4%	$7.2M+31.2%	$5.5M-21.2%	$7.0M
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$3.8M+21.8%	$3.1M+13.6%	$2.7M-32.8%	$4.1M-29.7%	$5.8M-19.4%	$7.2M+31.2%	$5.5M-21.2%	$7.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M-3.8%	$1.7M+17.2%	$1.4M-7.8%	$1.6M+85.2%	$842K-37.7%	$1.4M+247.3%	$390K+32.3%	$294K
Current Liabilities	$1.6M-3.8%	$1.7M+17.2%	$1.4M-7.8%	$1.6M+85.2%	$842K-37.7%	$1.4M+247.3%	$390K+32.3%	$294K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.2M+51.8%	$1.4M+9.7%	$1.3M-48.2%	$2.5M-49.1%	$5.0M-15.2%	$5.9M+14.7%	$5.1M-23.6%	$6.7M
Retained Earnings	-$77.6M-5.7%	-$73.4M-5.8%	-$69.4M-4.9%	-$66.2M-13.8%	-$58.1M-4.8%	-$55.4M-4.9%	-$52.8M-4.9%	-$50.4M

GLSI Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$7.3M-12.2%	-$6.5M-4.5%	-$6.2M-44.5%	-$4.3M-272.2%	-$1.2M-293.1%	-$293K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$4.4M	N/A	-$7.5M-365.8%	$2.8M-90.5%	$29.8M+13763.5%	$215K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$7.5M	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$2.7M-19.6%	-$2.2M-21.7%	-$1.8M+1.0%	-$1.9M+28.3%	-$2.6M-146.6%	-$1.0M+41.2%	-$1.8M+17.3%	-$2.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$3.4M+28.6%	$2.6M+429.7%	$492K+304.2%	$122K-89.7%	$1.2M-57.3%	$2.8M+825.0%	$299K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GLSI Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-623.1%-490.4pp	-132.7%-73.5pp	-59.2%-42.2pp	-17.0%-10.3pp	-6.7%	N/A
Return on Assets	-385.7%-258.6pp	-127.1%-69.1pp	-58.1%-41.3pp	-16.8%-10.3pp	-6.5%+12836.3pp	-12842.8%
Current Ratio	N/A	N/A	N/A	N/A	27.41+27.4	0.01
Debt-to-Equity	0.62+0.6	0.04+0.0	0.020.0	0.01-0.0	0.04+1.1	-1.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-190.0%+89.6pp	-279.6%-31.3pp	-248.3%	N/A	-53.6%-9.2pp	-44.4%+3.9pp	-48.3%	N/A
Return on Assets	-109.1%+19.7pp	-128.8%-10.3pp	-118.5%	N/A	-45.8%-9.8pp	-36.1%+8.8pp	-44.9%	N/A
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.74-0.4	1.17+0.1	1.10+0.5	0.62+0.4	0.17-0.1	0.23+0.2	0.08+0.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Theratechnologies Inc THTX

$155.9M

Climb Bio CLYM

$313.4M

Alpha Cognition ACOG

$130.0M

Coherus CHRS

$259.3M

Seres Therapeutics Inc MCRB

$88.9M

Frequently Asked Questions

Is Greenwich Lifesciences Inc profitable?

No, Greenwich Lifesciences Inc (GLSI) reported a net income of -$15.8M in fiscal year 2024.

What is Greenwich Lifesciences Inc's return on equity (ROE)?

Greenwich Lifesciences Inc (GLSI) has a return on equity of -623.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Greenwich Lifesciences Inc's operating cash flow?

Greenwich Lifesciences Inc (GLSI) generated -$7.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Greenwich Lifesciences Inc's total assets?

Greenwich Lifesciences Inc (GLSI) had $4.1M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Greenwich Lifesciences Inc spend on research and development?

Greenwich Lifesciences Inc (GLSI) invested $13.0M in research and development during fiscal year 2024.

How many shares does Greenwich Lifesciences Inc have outstanding?

Greenwich Lifesciences Inc (GLSI) had 13M shares outstanding as of fiscal year 2024.

What is Greenwich Lifesciences Inc's debt-to-equity ratio?

Greenwich Lifesciences Inc (GLSI) had a debt-to-equity ratio of 0.62 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Greenwich Lifesciences Inc's return on assets (ROA)?

Greenwich Lifesciences Inc (GLSI) had a return on assets of -385.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Greenwich Lifesciences Inc's cash runway?

Based on fiscal year 2024 data, Greenwich Lifesciences Inc (GLSI) had $4.1M in cash against an annual operating cash burn of $7.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Greenwich Lifesciences Inc's Piotroski F-Score?

Greenwich Lifesciences Inc (GLSI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Greenwich Lifesciences Inc's earnings high quality?

Greenwich Lifesciences Inc (GLSI) has an earnings quality ratio of 0.46x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.